1. Home
  2. CBIO vs PCB Comparison

CBIO vs PCB Comparison

Compare CBIO & PCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • PCB
  • Stock Information
  • Founded
  • CBIO 2003
  • PCB 2003
  • Country
  • CBIO United States
  • PCB United States
  • Employees
  • CBIO N/A
  • PCB N/A
  • Industry
  • CBIO
  • PCB Major Banks
  • Sector
  • CBIO
  • PCB Finance
  • Exchange
  • CBIO Nasdaq
  • PCB Nasdaq
  • Market Cap
  • CBIO 308.0M
  • PCB 289.7M
  • IPO Year
  • CBIO N/A
  • PCB N/A
  • Fundamental
  • Price
  • CBIO $14.29
  • PCB $22.10
  • Analyst Decision
  • CBIO Strong Buy
  • PCB Hold
  • Analyst Count
  • CBIO 5
  • PCB 2
  • Target Price
  • CBIO $25.60
  • PCB $22.25
  • AVG Volume (30 Days)
  • CBIO 97.6K
  • PCB 26.4K
  • Earning Date
  • CBIO 07-31-2025
  • PCB 10-23-2025
  • Dividend Yield
  • CBIO N/A
  • PCB 3.62%
  • EPS Growth
  • CBIO N/A
  • PCB 29.75
  • EPS
  • CBIO N/A
  • PCB 2.14
  • Revenue
  • CBIO N/A
  • PCB $102,259,000.00
  • Revenue This Year
  • CBIO N/A
  • PCB $22.59
  • Revenue Next Year
  • CBIO N/A
  • PCB $9.32
  • P/E Ratio
  • CBIO N/A
  • PCB $10.34
  • Revenue Growth
  • CBIO N/A
  • PCB 9.08
  • 52 Week Low
  • CBIO $10.83
  • PCB $16.00
  • 52 Week High
  • CBIO $21.40
  • PCB $22.45
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • PCB 57.65
  • Support Level
  • CBIO $13.50
  • PCB $21.97
  • Resistance Level
  • CBIO $16.00
  • PCB $22.41
  • Average True Range (ATR)
  • CBIO 0.79
  • PCB 0.38
  • MACD
  • CBIO 0.16
  • PCB 0.05
  • Stochastic Oscillator
  • CBIO 39.68
  • PCB 73.08

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About PCB PCB Bancorp

PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.

Share on Social Networks: